全文获取类型
收费全文 | 28002篇 |
免费 | 2750篇 |
国内免费 | 585篇 |
专业分类
耳鼻咽喉 | 178篇 |
儿科学 | 1046篇 |
妇产科学 | 823篇 |
基础医学 | 681篇 |
口腔科学 | 201篇 |
临床医学 | 2185篇 |
内科学 | 2553篇 |
皮肤病学 | 149篇 |
神经病学 | 254篇 |
特种医学 | 584篇 |
外国民族医学 | 64篇 |
外科学 | 3097篇 |
综合类 | 3479篇 |
现状与发展 | 2篇 |
预防医学 | 633篇 |
眼科学 | 110篇 |
药学 | 2275篇 |
18篇 | |
中国医学 | 813篇 |
肿瘤学 | 12192篇 |
出版年
2024年 | 64篇 |
2023年 | 354篇 |
2022年 | 837篇 |
2021年 | 1122篇 |
2020年 | 993篇 |
2019年 | 903篇 |
2018年 | 926篇 |
2017年 | 1007篇 |
2016年 | 1239篇 |
2015年 | 1166篇 |
2014年 | 1771篇 |
2013年 | 2239篇 |
2012年 | 1599篇 |
2011年 | 1795篇 |
2010年 | 1357篇 |
2009年 | 1407篇 |
2008年 | 1350篇 |
2007年 | 1508篇 |
2006年 | 1370篇 |
2005年 | 1120篇 |
2004年 | 908篇 |
2003年 | 809篇 |
2002年 | 721篇 |
2001年 | 658篇 |
2000年 | 537篇 |
1999年 | 506篇 |
1998年 | 409篇 |
1997年 | 409篇 |
1996年 | 297篇 |
1995年 | 269篇 |
1994年 | 257篇 |
1993年 | 175篇 |
1992年 | 145篇 |
1991年 | 139篇 |
1990年 | 117篇 |
1989年 | 107篇 |
1988年 | 91篇 |
1987年 | 82篇 |
1986年 | 65篇 |
1985年 | 83篇 |
1984年 | 72篇 |
1983年 | 61篇 |
1982年 | 44篇 |
1981年 | 50篇 |
1980年 | 47篇 |
1979年 | 40篇 |
1978年 | 40篇 |
1977年 | 26篇 |
1976年 | 29篇 |
1975年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
对我国目前麻风防治策略的思考 总被引:1,自引:0,他引:1
沈建平 《中华流行病学杂志》2009,30(10):1084-1086
1949-2008年我国累计登记麻风患者48万余例,主要分布在北纬38°以南的东南沿海和长江流域省份.新中国成立后,经过积极防治,至20世纪80年代初,以氨苯砜单疗治愈的患者达31万余例;1986年在全国普遍推广WHO联合化疗方案,至2008年底全国累计接受联合化疗的麻风患者近8万例. 相似文献
43.
目的 探讨针对肿瘤化学治疗所呈现的周期性规律,探索胃肠癌患者在化疗期间实施临床路径流程的可行性。方法 选择有病理诊断的晚期胃肠癌患者140例,随机分成实验组和对照组各70例,实验组实施临床路径流程,对照组实施传统流程,比较两组住院天数、医疗费用、医疗质量及患者满意度。结果 实验组患者的住院天数明显缩短(P<0.05),医疗费用明显降低(P<0.05),医疗质量及患者满意度均有较大幅度的提高(P<0.05)。结论 胃肠癌患者化疗期间实施临床路径流程切实可行。 相似文献
44.
Keishi Kashibuchi Kyoichi Tomita Jack A Schalken Haruki Kume Takumi Takeuchi Tadaichi Kitamura 《International journal of urology》2007,14(9):789-794
OBJECTIVES: To determine the value of the loss of expression of E-cadherin and cadherin associated molecules as useful markers for both prognosis and chemosensitivity in bladder cancer patients who have undergone radical cystectomy. PATIENTS AND METHODS: In 55 paraffin embedded specimens of radical cystectomy at our hospital from 1982 to 2000, the expression of E-cadherin, alpha-, beta- and gamma-catenin was examined by immunohistochemical staining. To evaluate the prognostic significance of these molecules, Kaplan-Meier survival curves were constructed and a statistical analysis was calculated by a log-rank test. A multivariate test (tumor stage, tumor grade, lymph node metastasis, configuration, the expression of E-cadherin, alpha-, beta- and gamma-catenin) was performed to detect prognostic markers. RESULTS: Normal expression was found in 33 cases (60.0%) for E-cadherin, 29 (52.7%) for alpha-catenin, 31 cases (56.4%) for beta-catenin, and 31 cases (56.4%) for gamma-catenin. The expression patterns for E-cadherin, alpha-, beta- and gamma-catenin were significantly correlated with each other (P < 0.01). Survival analysis showed a significant difference between normal and aberrant expression in each staining. A multivariate analysis revealed that the expression of alpha- catenin was an independent prognostic factor (P = 0.0191). In 23 patients that received adjuvant chemotherapy, there was a significant difference in survival between the normal and aberrant expression of alpha-catenin, but not other molecules. CONCLUSION: Alpha-catenin may not only be a good prognostic marker, but also one of key molecules that determine the chemosensitivities in patients with invasive bladder cancer. 相似文献
45.
Masafumi Kumano Hideaki Miyake Isao Hara Junya Furukawa Atsushi Takenaka Masato Fujisawa 《International journal of urology》2007,14(4):336-338
BACKGROUND: The objective of this study was to evaluate the efficacy and safety of first-line high-dose chemotherapy (HDCT) combined with peripheral blood stem cell transplantation (PBSCT) for patients with advanced extragonadal germ cell tumors (EGGCT). METHODS: Six male patients with advanced non-seminomatous EGGCT were treated with HDCT combined with PBSCT following 2-3 cycles of conventional-dose induction chemotherapy. The regimens used for HDCT were carboplatin, etoposide and ifosfamide (ICE) in five patients and ICE plus paclitaxel (T-ICE) in one patient, and that for induction therapy was cisplatin, etoposide and bleomycin (PEB) in all patients. As a rule, HDCT was continuously administered until alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin normalized (beta-HCG). RESULTS: Following 1-6 courses of HDCT (median, 4 courses), beta-HCG and AFP were normalized in all patients, and five and one patient were diagnosed as showing partial remission and stable disease, respectively. Five patients underwent surgical resection of residual tumors after HDCT, yielding necrotic tissue in two, mature teratoma in two, and viable cancer tissue in one, and the surgical margin was negative in all patients. At a median follow-up of 36 months, five patients were alive and disease-free, whereas the remaining one died of disease progression. Although all patients had grade 3 hematological toxicity, there was no treatment-related death by combining PBSCT. CONCLUSIONS: First-line HDCT with PBSCT could be safely administered to patients with advanced EGGCT, and the antitumor effect of this treatment was comparatively favorable. First-line HDCT therefore may represent an attractive option for patients with advanced EGGCT. 相似文献
46.
Tsuneharu Miki Yoichi Mizutani Hideyuki Akaza Seiichiro Ozono Taiji Tsukamoto Toshiro Terachi Katsusuke Naito Norio Nonomura Isao Hara Osamu Yoshida The Japan Blood Cell Transplantation Study Group for Testicular Germ Cell Tumor 《International journal of urology》2007,14(1):54-59
OBJECTIVE: Standard chemotherapy shows relatively low long-term survival in patients with poor-risk testicular germ cell tumor (GCT). First-line high-dose chemotherapy (HD-CT) may improve the result. High-dose carboplatin, etoposide, ifosfamide chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT) was investigated as first-line chemotherapy in patients with advanced testicular GCT. METHODS: Fifty-five previously untreated testicular GCT patients with Indiana 'advanced disease' criteria received three cycles of bleomycin, etoposide and cisplatin (BEP) followed by one cycle of HD-CT plus PBSCT, if elevated serum tumor markers were observed after three cycles of the BEP regimen. RESULTS: Thirty patients were treated with BEP alone, because the tumor marker(s) declined to normal range. Twenty-five patients received BEP and HD-CT. One patient died of rhabdomyolysis due to HD-CT. Three and six (13% and 25%) out of 24 patients treated with BEP and HD-CT achieved marker-negative and marker-positive partial responses, respectively. The other patients achieved no change. Fifteen (63%) are alive and 14 (58%) are free of disease at a median follow-up time of 54 months. Severe toxicity included treatment-related death (4%). CONCLUSIONS: HD-CT with peripheral stem cell support can be successfully applied in a multicenter setting. HD-CT demonstrated modest anticancer activity for Japanese patients with advanced testicular GCT and was well tolerated. This regimen might be examined for further investigation in randomized trials in first-line chemotherapy for patients with poor-risk testicular GCT. 相似文献
47.
Wing‐Hong Li Moon‐Tong Cheung Candace N.S. Ho Ting‐Pong Fung Kai‐Ming Ko Kelvin K.W. Yau 《Surgical Practice》2007,11(4):138-143
Aim: To examine the survival benefit of liver and lung resection for colorectal metastasis and the potential prognostic factors that affect patient survival. Methods: All patients who had resection of lung or liver metastasis for colorectal metastasis in Queen Elizabeth Hospital, Hong Kong from 1995 to 2004 were retrospectively reviewed. The overall and disease‐free survival was analysed, in particularly between liver and lung metastasis. All factors that may have affected the survival were entered into Cox's proportional hazards regression model to identify significant variables associated with survival. Results: At 5 years, the overall survival of patients who had resection of lung and liver metastasis was 44% and 38%, respectively; the disease‐free survival was 26% and 24%, respectively. Overall and disease‐free survival of patients with resection of lung metastasis was comparable to those with resection of liver metastasis. The differentiations of primary tumour and time to metastasis were shown to be significant prognostic factors influencing overall survival. Those patients with systemic chemotherapy after resection of colorectal metastasis demonstrated a significantly higher probability of overall survival. Conclusion: Resection of lung and liver metastases from colorectal origin was safe and both procedures improved survival. The use of chemotherapy after resection of metastasis significantly improved the overall survival. 相似文献
48.
Cancer chemotherapy with the application of several drugs is studied. The negative and inhibiting effect of the tumour on normal cells is taken into account. Under certain hypotheses, we determine the optimal regimen that minimizes the tumour burden at the end of a fixed period of therapy while maintaining several normal cell populations above prescribed levels. More precisely, it is demonstrated that the optimal drug administration corresponds to the strategy of intensive chemotherapy. 相似文献
49.
三维适形放疗联合肝动脉碘油栓塞化疗并热疗治疗原发性肝癌的疗效研究 总被引:1,自引:0,他引:1
目的:探讨原发性肝癌的肝动脉碘油栓塞化疗(TACE)、热疗、三维适形放疗(3DCRT)的综合治疗价值。方法:122例原发性肝癌患者进行前瞻性随机分组研究,综合治疗组64例,行TACE并3DCRT,结合热疗治疗。对照组58例3DCRT治疗,联合TACE。结果:1、2、3年生存率综合治疗组分别为85%、65%、39%,对照组分别为59%、30%、18%(P<0.05)两组毒副作用相似。结论:对于非手术切除的原发性肝癌患者,TA-CE,结合3DCRT并热疗,能明显提高疗效,而毒副作用不增加。 相似文献
50.
采用手术切除联合术后B超引导肝内门静脉区域化疗(简称PHPC)治疗胃肠道癌异时肝转移24例。随访4~54个月,结果:术后经3个疗程的PHPC,8例已存活肥18~48个月;13例分别经过2~11次的PHPC,已存活5~39p个月;另3例死亡。作者认为,对继发性肝癌采用手术切除配合术后B超引导的PHPC是一种延长患者生存期的有效联合治疗方案。 相似文献